Concierge Medicine Today: CEO, Jo Bhakdi and CMO, Dr. Monika Hagen
Episode 2: Quantgene and Early Cancer Detection Technologies
Innovations in deep sequencing, artificial intelligence and big data are now available direct-to-consumers through an integrated expert-driven system.
SANTA MONICA, Calif., May 11th, 2020 — Quantgene, a precision medical company and leader in deep genomics, launched its proprietary cancer and health protection system for patient use this past weekend. This will be a direct-to-consumer product, allowing patients to sign up through the website and be connected with top medical professionals in the field of genomic medicine.
In recent years, hereditary genetic testing has been garnering significant recognition as one of the earliest protection options for patients, and, in many cases, is considered the first line of defense against a number of chronic, degenerative diseases. In looking at cancer in particular, identification in its earliest stages increases 5-year survivability by approximately 61% across 10 cancer types. The genetic testing offered through Quantgene will analyze a patient’s individualized risks for developing some of the deadliest forms of cancer throughout their lifetime, and patients will also be given the option of extending their testing to look for underlying genetic markers indicating the progression of a number of common diseases.
“Our mission is to protect the lives of our members through advanced medical technology,” said Jo Bhakdi, founder and CEO of Quantgene. “We build and source these technologies ourselves and focus on one question: what new technologies are available that work and can add significant protection to our members?”
Quantgene launched its products for clinical use through its overarching program, SERENITY. SERENITY is being offered through a tiered structure, providing patients with a variety of plans to attain the level of insight that they are seeking.